These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 9833562)

  • 1. [Acquired dysfibrinogenemia].
    Mori T; Ikeda Y
    Ryoikibetsu Shokogun Shirizu; 1998; (21 Pt 2):529-31. PubMed ID: 9833562
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired dysfibrinogenemia following allogeneic bone marrow transplantation.
    Mori T; Murata M; Wakui M; Muto A; Ishida A; Tanosaki R; Okamoto S; Ikeda Y
    Am J Hematol; 1997 Dec; 56(4):294-5. PubMed ID: 9395195
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis of hypofibrinogenemias found on routine coagulation screening tests and identification of heterozygous dysfibrinogenemia or fibrinogen deficiency].
    Hirota-Kawadobora M; Ishikawa S; Fujihara N; Wakabayashi S; Kamijo Y; Yamauchi K; Terasawa F; Okumura N; Katsuyama T
    Rinsho Byori; 2007 Nov; 55(11):989-95. PubMed ID: 18154029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains.
    Martinez J; MacDonald KA; Palascak JE
    Blood; 1983 Jun; 61(6):1196-202. PubMed ID: 6839020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis.
    Narvaiza MJ; Fernández J; Cuesta B; Páramo JA; Rocha E
    Ric Clin Lab; 1986; 16(4):563-8. PubMed ID: 3576054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The abnormal carbohydrate composition of the dysfibrinogenemia associated with liver disease.
    Martinez J; Keane PM; Gilman PB; Palascak JE
    Ann N Y Acad Sci; 1983 Jun; 408():388-96. PubMed ID: 6575696
    [No Abstract]   [Full Text] [Related]  

  • 7. Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin lambda light chain.
    Dear A; Brennan SO; Sheat MJ; Faed JM; George PM
    Haematologica; 2007 Nov; 92(11):e111-7. PubMed ID: 18024387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrinogen Denver: a dysfibrinogenemia associated with an abnormal Reptilase time and significant bleeding.
    Walter S; Stabler S; Lefkowitz JB
    Haemophilia; 2006 Jul; 12(4):393-7. PubMed ID: 16834739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Congenital dysfibrinogenemia (fibrinogen Giessen).
    Krause WH; Heene DL; Lasch HG
    Thromb Diath Haemorrh; 1973 Jun; 29(3):547-61. PubMed ID: 4761823
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinogen Montreal. A new case of congenital dysfibrinogenemia with defective aggregation of monomers.
    Lacombe M; Soria J; Soria C; D'Angelo G; Lavallee R; Bonny Y
    Thromb Diath Haemorrh; 1973 Jun; 29(3):536-46. PubMed ID: 4761822
    [No Abstract]   [Full Text] [Related]  

  • 11. Modified approach to fibrinogen replacement in the setting of dysfibrinogenaemia.
    Chandler JB; Siddon AJ; Bahel P; Torres R; Rinder HM; Tormey CA
    J Clin Pathol; 2019 Feb; 72(2):177-180. PubMed ID: 30463936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysfibrinogenemia (fibrinogen Wilmington) due to a novel Aalpha chain truncation causing decreased plasma expression and impaired fibrin polymerisation.
    Brennan SO; Mosesson MW; Lowen R; Frantz C
    Thromb Haemost; 2006 Jul; 96(1):88-9. PubMed ID: 16807657
    [No Abstract]   [Full Text] [Related]  

  • 13. Acquired dysfibrinogenemia secondary to multiple myeloma.
    Kotlín R; Sobotková A; Riedel T; Salaj P; Suttnar J; Reicheltová Z; Májek P; Khaznadar T; Dyr JE
    Acta Haematol; 2008; 120(2):75-81. PubMed ID: 18841003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new congenital abnormality of human fibrinogen. Fibrinogen Bethesda II.
    Gralnick HR; Givelber HM; Finlayson JS
    Thromb Diath Haemorrh; 1973 Jun; 29(3):562-71. PubMed ID: 4761824
    [No Abstract]   [Full Text] [Related]  

  • 15. Elevated fibrinogen in an acute phase reaction prolongs the reptilase time but typically not the thrombin time.
    Van Cott EM; Smith EY; Galanakis DK
    Am J Clin Pathol; 2002 Aug; 118(2):263-8. PubMed ID: 12162688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
    Miesbach W; Galanakis D; Scharrer I
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):366-70. PubMed ID: 19357502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of acquired dysfibrinogenemias. I. Importance of the comparative study of 2 methods of determination of fibrinogen for the demonstration of dysfibrinogenemias].
    Papilian M; Niţă I
    Stud Cercet Med Interna; 1969; 10(6):525-35. PubMed ID: 5370609
    [No Abstract]   [Full Text] [Related]  

  • 18. Fibrinogen Łódź: a new cause of dysfibrinogenemia associated with recurrent thromboembolic arterial events.
    Treliński J; Witkowski M; Chojnowski K; Neerman-Arbez M; Wypasek E; Undas A
    Pol Arch Intern Med; 2019 Dec; 129(12):934-935. PubMed ID: 31596272
    [No Abstract]   [Full Text] [Related]  

  • 19. [Dysfibrinogenemia].
    Philippe N
    Pediatrie; 1972; 27(1):93-100. PubMed ID: 4557225
    [No Abstract]   [Full Text] [Related]  

  • 20. A novel Asp344Val substitution in the fibrinogen gamma chain (fibrinogen Caen) causes dysfibrinogenemia associated with thrombosis.
    Robert-Ebadi H; Le Querrec A; de Moerloose P; Gandon-Laloum S; Borel Derlon A; Neerman-Arbez M
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):697-9. PubMed ID: 18832913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.